Damora Therapeutics ownership update: Amendment No. 1 to a Schedule 13G/A reports that Point72-related entities and Steven A. Cohen beneficially hold 1,193,708 shares of Damora Therapeutics common stock, equal to 2.0% of the class as of the close of business on March 31, 2026. The shares are reported as held by an investment fund managed by Point72 Asset Management, L.P., with voting and dispositive power shared among Point72 entities and Mr. Cohen pursuant to an investment management agreement.
Positive
None.
Negative
None.
Insights
Point72 reports a 2.0% stake in Damora as of March 31, 2026.
Row 9 of the cover page shows 1,193,708 shares (2.0%) beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Steven A. Cohen via an investment fund they manage. The filing is an Amendment No. 1 to a Schedule 13G/A and is dated as of March 31, 2026.
The statement attributes shared voting and dispositive power to the reporting persons and notes that each reports owning no shares directly. Subsequent filings or fund disclosures would be the source for changes; cash‑flow treatment or any planned disposition is not stated in the provided excerpt.
Filing clarifies ownership structure and attribution.
The statement explains that Point72 Asset Management maintains investment and voting power for an investment fund and that Point72 Capital Advisors Inc. is the general partner; Mr. Cohen controls those entities. The filing includes the standard Section 13 qualified disclaimer about beneficial ownership.
Ownership figures are stated "as of the close of business on March 31, 2026"; the amendment and signatures are dated May 15, 2026 in the excerpt.
Key Figures
Shares beneficially owned:1,193,708 sharesPercent of class:2.0%CUSIP:36322Q206+1 more
4 metrics
Shares beneficially owned1,193,708 sharesas of March 31, 2026
"The information required by Item 4(a) is set forth in Row 9 of the cover page"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive powerregulatory
"Shared Dispositive Power 1,193,708.00"
investment management agreementfinancial
"Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
qualified disclaimerregulatory
"The filing of this statement should not be construed as an admission that any of the foregoing persons... is the beneficial owner"
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 1)
Damora Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.00001 per share
(Title of Class of Securities)
36322Q206
(CUSIP Number)
03/31/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
36322Q206
1
Names of Reporting Persons
Point72 Asset Management, L.P.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,193,708.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,193,708.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,193,708.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.0 %
12
Type of Reporting Person (See Instructions)
PN
SCHEDULE 13G
CUSIP Number(s):
36322Q206
1
Names of Reporting Persons
Point72 Capital Advisors, Inc.
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,193,708.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,193,708.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,193,708.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.0 %
12
Type of Reporting Person (See Instructions)
CO
SCHEDULE 13G
CUSIP Number(s):
36322Q206
1
Names of Reporting Persons
Steven A. Cohen
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
1,193,708.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
1,193,708.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
1,193,708.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
2.0 %
12
Type of Reporting Person (See Instructions)
IN
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
Damora Therapeutics, Inc.
(b)
Address of issuer's principal executive offices:
221 Crecent Street, Building 23, Suite 105, Waltham, MA 02453
Item 2.
(a)
Name of person filing:
This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.00001 per share ("Shares"), of Damora Therapeutics, Inc. (f/k/a Galecto, Inc.) held by an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to the Shares held by an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to the Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
Each of Cubist Systematic Strategies, LLC, Point72 (DIFC) Limited and Point72 Asia (Singapore) Pte. Ltd. are relying advisers on the Form ADV of Point72 Asset Management and each acts as a sub-advisor with respect to a portion of the Shares reported herein.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)
Citizenship:
Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)
Title of class of securities:
Common Stock, par value $0.00001 per share
(e)
CUSIP No.:
36322Q206
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
(b)
Percent of class:
2.0%
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(ii) Shared power to vote or to direct the vote:
The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iii) Sole power to dispose or to direct the disposition of:
The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
(iv) Shared power to dispose or to direct the disposition of:
The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on March 31, 2026.
Item 5.
Ownership of 5 Percent or Less of a Class.
Ownership of 5 percent or less of a class
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
See Item 2(a).
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
What stake does Point72 report in Damora Therapeutics (DMRA)?
Point72 reports beneficial ownership of 1,193,708 shares, representing 2.0% of Damora Therapeutics' common stock as of March 31, 2026. The shares are held by an investment fund managed by Point72 Asset Management.
Which entities and individuals are named on the Schedule 13G/A for DMRA?
The filing lists Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen as reporting persons, with shared voting and dispositive power over the reported shares.
Are the reported shares held directly by the reporting persons?
No. The filing states Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own no shares directly; they report control via an investment fund and related management arrangements.
What date is used for the ownership calculation in the filing?
Ownership amounts are stated as of the close of business on March 31, 2026, per Row 9 of the cover page referenced in Item 4(a).
Does the filing disclose any planned sale or purchase of DMRA shares?
The excerpt does not disclose any planned sales or purchases. It states voting and dispositive powers and includes the routine Section 13 qualified ownership language without describing transactions.
